• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Trop Anim Health Prod . Antibody kinetics and shedding dynamics of MERS-CoV in dromedary camels from different production systems in Kenya: a longi

tetano

Editor, Senior Moderator
Trop Anim Health Prod


. 2026 Mar 12;58(2):169.
doi: 10.1007/s11250-026-04981-3.
Antibody kinetics and shedding dynamics of MERS-CoV in dromedary camels from different production systems in Kenya: a longitudinal cohort study

Rinah Sitawa Wangila[SUP] 1 [/SUP], Thomas Nyariki[SUP] 1 2 [/SUP], Dickson Machira Nyaguthii[SUP] 3 4 [/SUP], Timothy Muthui Wachira[SUP] 3 [/SUP], Joshua Kimutai[SUP] 1 [/SUP], Allan Azegele[SUP] 5 [/SUP], Romona Ndanyi[SUP] 5 [/SUP], James Ngoci[SUP] 5 [/SUP], Bridgit Muasa[SUP] 5 [/SUP], George Njogu[SUP] 5 [/SUP], Peter Baaro Gathura[SUP] 3 [/SUP], Emma G Gardener[SUP] 6 [/SUP], El Masry Ihab[SUP] 6 [/SUP], Joseph Kamau[SUP] 7 [/SUP], Robert Ofwete[SUP] 8 [/SUP], Chitwambi Makungu[SUP] 9 [/SUP], Aminu Shittu[SUP] 10 [/SUP], Charles Bebay[SUP] 1 [/SUP], Folorunso O Fasina[SUP] 11 12 [/SUP]


Affiliations
Abstract

Understanding long-term antibody kinetics in different camel production systems is crucial for risk assessment for Middle East respiratory syndrome coronavirus (MERS-CoV), a zoonotic pathogen first detected in humans in Saudi Arabia. Though the virus is endemic in dromedary camels across Africa, the Middle East, and parts of South Asia, zoonotic transmission outside of the Arabian Peninsula is undocumented. A retrospective analysis of longitudinal surveillance data of MERS-CoV was conducted on 2460 serum samples collected from 174 camels in three high-risk counties of Kenya from April 2018 to March 2021. Data were analyzed using descriptive statistics, logistic regression, and survival analysis. A total of 93/174 (53.4%) camels were seropositive at least once (animal-level), while 882/2460 (35.85%) of all serum samples tested seropositive (sample-level). Data were analyzed using descriptive statistics, logistic regression and survival analysis. A total of 93/174 (53.4%) camels were seropositive at least once. All camels in the pastoral system seroconverted, exhibiting significantly higher odds of seropositivity (OR: 9.4) compared to ranched camels, and camels above 3 years (OR: 21.2) are more likely to be seropositive compared to young ones. The median duration of seropositivity was 21 days (IQR: 11–53), varying significantly by geographical site. Camels from Garissa and Soysambu have 97% (aOR: 0.03 (CI[SUB]95%[/SUB]: 0.001–0.79; p = 0.035) and 98% (aOR: 0.02 (CI[SUB]95%[/SUB]: 0.001–0.48; p = 0.015) longer durations of seropositivity than those from Isiolo. The study demonstrates the spatiotemporal and biological variability of antibody levels, indicative of fluctuations in viral exposure and the resultant immune response among the camel herds. Thus, camel production practices, not just seroprevalence, drive MERS-CoV infection dynamics, demanding surveillance and stewardship strategies that are tailored to specific production systems to effectively mitigate zoonotic risk.
Supplementary Information: The online version contains supplementary material available at 10.1007/s11250-026-04981-3.

Keywords: Antibody titres and nasal shedding dynamics; Middle East respiratory syndrome coronavirus; Retrospective review.

 
Back
Top